MaxCyte, Inc. - Common Stock (NQ:MXCT)

0.7763 +0.0240 (+3.19%)

Streaming Delayed Price Updated: 12:24 PM EST, Feb 24, 2026 Add to My Watchlist

Price and Volume

Volume	375,276
Open	0.7651
Bid (Size)	0.7755 (600)
Ask (Size)	0.7770 (1,000)
Prev. Close	0.7523
Today's Range	0.7375 - 0.7902
52wk Range	0.6434 - 3.970
Shares Outstanding	105,482,558
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

Today 8:05 EST

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

February 23, 2026

From MaxCyte, Inc

Via GlobeNewswire

Performance

YTD	-49.9%	-49.9%
1 Month	-31.3%	-31.3%
3 Month	-53.5%	-53.5%
6 Month	-44.2%	-44.2%
1 Year	-79.4%	-79.4%

More News

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

January 12, 2026

From MaxCyte, Inc

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

MaxCyte Announces Planned CFO Transition in 2026

November 12, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

November 12, 2025

From MaxCyte, Inc

Via GlobeNewswire

Insights into MaxCyte's Upcoming Earnings ↗

November 11, 2025

Via Benzinga

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

November 05, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

October 08, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

October 06, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

September 22, 2025

From MaxCyte, Inc

Via GlobeNewswire

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

August 11, 2025

Via Benzinga

Thursday's session: top gainers and losers ↗

August 07, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 07, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

August 07, 2025

Via Chartmill

Traders are paying attention to the gapping stocks in Thursday's session. ↗

August 07, 2025

Via Chartmill

MaxCyte (MXCT) Q2 Revenue Drops 18% ↗

August 06, 2025

Via The Motley Fool

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

August 06, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Platform License Agreement with Adicet Bio

August 04, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

July 31, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

July 09, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

June 11, 2025

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

May 07, 2025

From MaxCyte, Inc

Via GlobeNewswire

Frequently Asked Questions

Is MaxCyte, Inc. - Common Stock publicly traded?

Yes, MaxCyte, Inc. - Common Stock is publicly traded.

What exchange does MaxCyte, Inc. - Common Stock trade on?

MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MaxCyte, Inc. - Common Stock?

The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market

What is the current price of MaxCyte, Inc. - Common Stock?

The current price of MaxCyte, Inc. - Common Stock is 0.7763

When was MaxCyte, Inc. - Common Stock last traded?

The last trade of MaxCyte, Inc. - Common Stock was at 02/24/26 12:24 PM ET

What is the market capitalization of MaxCyte, Inc. - Common Stock?

The market capitalization of MaxCyte, Inc. - Common Stock is 81.89M

How many shares of MaxCyte, Inc. - Common Stock are outstanding?

MaxCyte, Inc. - Common Stock has 82M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.